Caspase activation is a component of a number of neurodegenerative disorders, including stroke. In this study, the authors describe a multiplexed assay for caspase 3 activation, nuclear condensation, and cell viability in a neuronal precursor cell line Ntera-2, injured with staurosporine and etoposide. Using a high-content screening approach, cells were identified by staining with the nuclear stain Hoechst 33342; cell viability was measured by staining cells with YoPro-1, which is taken up by damaged cells but excluded from healthy cells; and caspase 3/7 activation was detected using the cell-permeable probe PhiPhi-Lux, which becomes fluorescent when cleaved by active caspase 3 or 7. These 3 dyes were detected simultaneously using a 4band pass filter set on a Cellomics Arrayscan. The authors used peptide-fmk inhibitors selective for a variety of caspases, demonstrating that the injury is mediated primarily through caspase 3 or 7, although other caspases or related proteases may play a minor role. The general caspase inhibitor zVAD-fmk was able to block cell death and caspase activation with the highest potency. The caspase 3 selective inhibitor DEVD-fmk was almost as potent as zVAD-fmk; other peptide caspase inhibitors displayed only modest inhibition of cell death. This assay was also used as a high-content screening tool for the evaluation of novel caspase 3 inhibitors for the potential treatment of degenerative disorders. (Journal of Biomolecular Screening 2006:296-302) 
INTRODUCTION
I N ADDITION TO BEING A DEVELOPMENTAL PROCESS, which is critical in controlling cell number and organogenesis, apoptosis is a key mechanism underlying the death of many cells in degenerative disorders. This is particularly true in the CNS following an acute injury, such as head trauma or stroke, or as a result of chronic disorders, such as Alzheimer disease. Apoptosis is characterized by a series of highly regulated events, initiated by cell surface receptors, such as cytokine receptors, or intracellular events, such as free radical production or toxic protein-aggregate accumulation. The end result of these apoptotic mechanisms is the death of the cell and its clearance from the body. A dysregulation of these apoptotic pathways can lead to an accelerated and widespread death of cells in the affected tissue, resulting in a pathological condition.
Among the key mediators of these signaling and degradation events are the caspase family of proteolytic enzymes. There are at least 14 members of this family, which have been classified based on their structural homology, substrate preference, and function. Caspases have a proteolytic preference for aspartate residues in the P1 position and differing preferences for residues in the P2, P3, and P4 positions determining substrate specificity. 1, 2 Caspases are expressed as proenzymes, which require proteolytic cleavage to become active. Caspases 2, 8, 9, and 10 have been identified as playing a role in the initiation of the apoptotic process and have large N-terminal pro-domains. Caspases 3, 6, and 7 have been linked to the execution of the apoptotic response and are generally downstream of the initiator caspases. Most of the understanding of the substrate selectivity of caspases is derived from the use of tetrapeptide inhibitors in biochemical assays. 1, 2 It has been shown that zVAD-fmk will nonselectively inhibit all caspases; DEVD-fmk displays selectivity toward caspases 3 and 7; WEHD-fmk is selective for caspase 1 and, to a lesser extent, caspase 8; YVAD-fmk is selective for caspase 1; and LEHD-fmk is selective for caspase 9.
Among the effector caspases, caspase 3, along with caspase 7, has a preference for the cleavage site sequence DEVD 1 and has been implicated in playing a pivotal role in neuronal cell death in the neonatal and adult brains and is of particular interest for the de-velopment of therapeutics to treat CNS degenerative disorders. The development of compounds to inhibit native caspase activity requires that the enzyme activity be measured in a cellular context. This can either be done by measuring distal events, such as DNA fragmentation, membrane remodeling, or mitochondrial activity. 3 Alternatively, it can be measured directly, which has traditionally involved lysis of the cells and measurement of caspase activity from the lysate. Caspase activity has also been measured in live cells using tandem fluorescent protein reporters linked by a peptide containing a caspase cleavage site and measuring fluorescent resonance energy transfer (FRET). 4 This approach is limited by the need to generate stable cell lines or to transiently express the construct, which is difficult in many cell types. It is also problematical to measure cell-based FRET in a high-content screening platform, requiring more specialized equipment.
To measure the activity of caspase 3/7 in live cells, we used the cell-permeable fluorescent reporter PhiPhi-Lux R 2 D 2 , which has been previously reported to measure caspase activity by flow cytometry and confocal microscopy in thymocytes, lymphocytes, and osteosarcoma cells. [5] [6] [7] The principle by which this reporter works is that 2 identical fluorophores, excited at 633 nm, are linked via a peptide sequence containing a consensus cleavage site for caspase 3/7 (DEVDGI). Under noncaspase activating conditions, the close association of fluorophores induces a quenching event. This reporter is able to diffuse into the cell, but upon cleavage by active caspase 3/7, the free fluorophores are released, becoming fluorescent and also unable to exit the cell because of their charge. We used a Cellomics Arrayscan II to measure the signal from the caspase 3/7 reporter on a cell-by-cell basis in conjunction with the nuclear dye, Hoechst 33342, and the cell viability dye, YoPro-1, which is a green fluorescent molecule excluded from healthy cells and integrates into the nucleus of compromised or apoptotic cells. 8 As a model system for studying the inhibition of caspases, we used the multipotent neuronal precursor cell Ntera-2 (NT2), which is derived from a lung metastasis of a testicular teratocarcinoma. 9 These cells have the capacity to differentiate into neurons in the presence of retinoic acid, although we used the undifferentiated cells in this study. 10 The NT2 cells were injured using either the kinase inhibitor staurosporine or the DNA topoisomerase inhibitor etoposide. In this study, we provide a validation of this multiparameter approach to caspase activation and cell viability in addition to demonstrating its utility for screening newly identified caspase inhibitors.
METHODS

NT2 assay
NT2 cells were plated at 1.8 × 10 4 cells/mL in 200 µL Dulbecco's modified Eagle medium (DMEM) with 10% fetal bovine serum (FBS) 2 days prior to the assay. They were treated with either staurosporine (100 nM) or etoposide (1 µM) at the same time as peptide-fmk (Enzyme Systems) or small-molecule caspase 3 inhibitors. Cells were then maintained for 20 h prior to the addition of staining solution containing YoPro-1 (Molecular Probes), Hoechst 33342 (Molecular Probes), and PhiPhi-Lux R 2 D 2 (OncoImmunin). The final concentration of Hoechst 33342 was 2 mg/mL, PhiPhi-Lux was 1 µM, and YoPro-1 was 0.4 µM. Staining of the cells with these reagents was quantified using a Cellomics ArrayScan II after a 2-h incubation.
Cellomics protocols
The Cellomics general screen protocol was used to measure PhiPhi-Lux cleavage and YoPro-1 staining of the nucleus in NT2 cells. PhiPhi-Lux was measured in the Cy5 filter set (633 nm excitation), and YoPro-1 was measured using the FITC filter set (488 nm excitation). Staining of the nucleus with the DNA interchelating dye Hoechst 33342 was measured using the DAPI filter set and was used for the identification of cells and for focusing. Based on an initial mask encompassing the nucleus, a secondary mask based on the nucleus and most of the cytoplasm (nuclear diameter plus 2 pixels) was used to measure the intensity of YoPro-1 and PhiPhi-Lux. Another mask using a concentric ring outside of this inner mask was set to fall outside the cell and was separated from the inner mask by a 2-pixel offset to measure the fluorescence background in the FITC and Cy5 channels. This background intensity measurement was used to measure the difference intensity in the cell (inner mask) above background (outer mask) for each cell (Fig. 1B) . A cell was scored as being positive for either PhiPhi-Lux or YoPro-1 if the intensity was above a threshold value, which was statistically significant from the control.
RESULTS
Caspase activity was measured in live NT2 cells using the cellpermeable reporter of caspase activity PhiPhi-Lux 5 in the presence of various tetra-peptide caspase inhibitors to characterize the signature of caspase activation induced by apoptotic insults. Cell viability was measured concurrently in the same cells using the DNA stain, YoPro-1, which selectively enters and labels the nuclei of injured or apoptotic cells. 11 NT2 cells were treated with the kinase inhibitor staurosporine (100 nM) or the DNA-topoisomerase inhibitor etoposide (1 µM) to induce apoptosis by 2 different mechanisms of action and subsequently treated with peptide-fmk caspase inhibitors (3, 10, and 30 µM). Caspase activity and cell viability measurements were taken using a Cellomics Arrayscan after an 18-h insult and treatment with caspase inhibitor. Figure 1A shows a representative red/ green/blue (RGB) image field taken on the Cellomics Arrayscan showing the activation of the PhiPhi-Lux probe (red), YoPro-1 (green), and the nuclear stain Hoechst 33342 (blue) in control and staurosporine-treated cells. In the injured cells, the nucleus is also condensed, which is a typical phenotype of apoptotic cells; these nuclei also stain with YoPro-1, indicating that the cells are apoptotic and have become permeable to this fluorophore, 11 which is difficult to see in this composite image. Figure 1B shows individual images from the DAPI, FITC, and Cy5 channels for the nucleus, YoPro-1, and PhiPhi-Lux, respectively. In cells treated with staurosporine (or etoposide), there is a pronounced increase in the number of apoptotic cells, with condensed nuclei staining for YoPro-1 and PhiPhi-Lux. These images also show the areas in A B which the software calculates the fluorescence in the nucleus and in a ring outside of this for the background. Each image is from a single field, and a group of cells within this field in each channel has been magnified to show more clearly the area within the cell used to make measurements (Fig. 1B) . As seen from the frequency distribution of YoPro-1 intensity ( Fig. 2A) in control (upper panel) and staurosporine-treated (lower panel) cells, there is virtually no staining of control cells with YoPro-1, in contrast to those treated with staurosporine for 18 h. A histogram of the intensity distribution of PhiPhi-Lux fluorescence (Fig. 2B) shows the increase in caspase 3 activity following 18 h of staurosporine treatment. The difference in PhiPhi-Lux intensity between control and staurosporine-treated cultures is not as large as with YoPro-1 but is easily quantified.
Inhibition of caspase 3/7 activation, measured using PhiPhi-Lux, and rescue of cell viability, measured with YoPro-1, were achieved with the peptide inhibitor zVAD-fmk and DEVD-fmk (Fig. 3A) . In contrast, there was only moderate inhibition of PhiPhi-Lux activation and cell rescue using WEHD-fmk, and both LEHD-fmk and YVAD-fmk were ineffective at preventing probe cleavage and apoptosis (Fig. 3A) . Using another pro-apoptotic agent, etoposide, all the peptide-fmks, apart from LEHD-fmk, were more potent at inhibiting PhiPhi-Lux activation. However, their relative activity was unchanged (Fig. 3B) . Results are grouped by peptide, with caspase and YoPro-1 data side by side on the x-axis of each graph.
This assay was subsequently used to screen compounds that had previously been identified as caspase inhibitors in a cell-free in vitro assay for cell-based inhibition of caspase activity and cell viability. Compounds were screened initially at 2 and 20 µg/mL in NT2 cells treated with staurosporine (100 nM) for 18 h and caspase 3/7 and rescue of cell viability measured as before using PhiPhi-Lux and YoPro-1 (Fig. 4A) . A large number of the compounds tested had high negative values for both caspase inhibition and rescue due to the compound being highly cytotoxic. It is unlikely that the high fluorescence observed for these toxic compounds is a result of compound fluorescence because this would increase the extracellular fluorescence to the same extent as intracellularly, unless it preferentially partitioned inside the cell. These toxic compounds were significantly more toxic than staurosporine alone and demonstrate the importance of performing a cell-based screen following identification of leads to concentrate on compounds that have activity against the target in a cell and to identify potential compound toxicity at an early point.
Compounds that inhibited caspase 3 activity and inhibited the cleavage of the PhiPhi-Lux probe in this assay also demonstrated a clear correlation with improved cell viability and a reduction in apoptotic cells, measured using YoPro-1 (Fig. 4B) . At the higher compound concentration (20 µg/mL), there was a strong positive correlation between caspase 3/7 and cell rescue for those compounds that inhibit PhiPhi-Lux cleavage (R 2 = 0.65), although the correlation was less at the 2-µg/mL dose of compound (R 2 = 0.3) (Fig. 4B) . Compounds identified as promising leads based on their ability to inhibit caspase activity and rescue cells in the 2-point assays were then evaluated over a concentration range from 10 nM up to 30 µM to determine IC 50 s, a selection of which are shown in A B Figure 5 .
Most of the chemical leads tested had potency similar to the peptide inhibitor zVAD-fmk, which had an IC 50 for PhiPhi-Lux cleavage of 11 µM. However, 1 compound tested, WAY-2, was considerably more potent at blocking PhiPhi-Lux cleavage with an IC 50 of 141 nM.
DISCUSSION
Caspases are an important class of drug targets, particularly in the CNS, both in terms of adult and neonatal disease processes. We have developed an effective assay to screen for compounds that protect neuronal precursor cells from apoptotic cell death by inhibiting the activity of human caspase 3/7. This assay was used as a secondary procedure in our screening cascade, following identification of caspase 3 inhibitors in a cell-free biochemical assay. It provides a reproducible and robust method for assaying the potency of caspase 3 inhibitors against the native enzyme in a cellbased model of apoptosis by monitoring the activity of the molecular target simultaneously with cell viability. This assay was also able to provide us with valuable information on any cytotoxicity caused by the compounds being tested.
Caspase 3 is one of the major apoptotic enzymes activated as a result of ischemic injury in the CNS, both in newborns and in adults, leading to major debilitating pathologies. 12, 13 This insult targets neurons, which, if not killed in the ischemic core at the site of injury, die by a delayed cell death in an area (penumbra) spreading out from the ischemic core. 14, 15 Recovery from ischemic injury can also be hindered by the death of neuronal stem cells and precursors as a result of the delayed cell death in the ischemic penumbra. 16 The cell type used in this assay, NT2, is derived from a human teratocarcinoma and has the ability to differentiate into functional postmitotic neurons, whereas the dividing precursor cells, which we are using, possess characteristics and expression patterns similar to neuronal precursor cells. 9, 10, 17 Agents that activate cell death pathways are useful tools in developing cell-based systems that mimic the in vivo stress resulting in the activation of cell death pathways, without the variability often introduced by attempting to directly reproduce the injury. We chose to use 2 chemicals in our model-staurosporine, 18 which is a broad-specificity kinase inhibitor, and etoposide, which is a DNA topoisomerase inhibitor. 19 In the screening against the compounds we identified as caspase 3 inhibitors, we used staurosporine as our apoptotic insult.
Peptide-based inhibitors of proteases-in this case, caspaseshave been widely used as enzyme inhibitors. Their mode of action is to act as un-cleavage substrates for the protease and therefore remain bound in the active site and compete for endogenous substrate. In both staurosporine-and etoposide-injured NT2 cells, the most effective tetrapeptide-fmk at blocking the activation of the fluorescent reporter of caspase 3/7 activity was zVAD-fmk, which is relatively nonselective among the caspase family 1 and was equally effective against both injuries. This would suggest that multiple caspase-dependent signaling pathways are activated following both of these insults and contribute to the apoptotic pathway. The next most effective peptide inhibitor with some degree of selectivity was DEVD-fmk, which is a selective inhibitor for caspases 3 and 7. 1 It would be expected that zVAD-fmk and DEVD-fmk would have the greatest effect on PhiPhi-Lux cleavage because the reporter has the cleavage site DEVDGI, which is selective for caspases 3 and 7. If the compounds tested are inhibiting caspases upstream of caspases 3 and 7, such as caspase 1 or 8, it would be expected that there would be a decrease in the activity of caspases 3 and 7, resulting in less PhiPhi-Lux cleavage, unless the 4. (A) Distribution of percentage cell rescue (measured using YoPro-1) and percentage caspase inhibition (measured using PhiPhi-Lux) for compounds previously identified as caspase 3 inhibitors and tested here at 2 and 20 µg/mL. Cells were injured with staurosporine (100 nM) for 18 h. Many of the compounds were profoundly toxic, resulting in high negative values for cell rescue and inhibition of caspase activity. (B) Compounds that were effective at inhibiting caspase activity in cells at 20 µg/mL are also effective at rescuing cell viability with a positive correlation (R 2 = 0.65). There was also a positive but weaker correlation for compounds at the lower concentration of 2 µg/mL (R 2 = 0.30). fore not surprising that the inhibition of caspase 9 does not result in a decrease in caspase 3/7 activity, although it might be expected that cell viability would be improved, which did not occur. One disadvantage to the cell-based caspase assay described here is that it uses a single probe to measure the activity of caspase 3/7. It would be able to more clearly dissect the signaling pathway and order of caspase activation involved if multiple probes using different fluorophores were available and could be used in a multiplexed assay. In summary, this assay is an effective screen for small-molecule caspase 3/7 inhibitors in a cell-based system of apoptotic cell death. It has proved to be very successful for this purpose and allowed for the screening of compounds of interest in a multiparameter assay providing cell-based information on caspase inhibition, cell rescue, and compound cytotoxicity and to correlate these parameters.
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